Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: vir.bio
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $23.00 → $9.00 | Overweight → Neutral | JP Morgan |
| 9/8/2023 | $23.00 → $14.00 | Buy → Neutral | BofA Securities |
| 3/6/2023 | $35.00 → $34.00 | Neutral → Overweight | JP Morgan |
| 2/21/2023 | $41.00 → $53.00 | Neutral → Buy | Goldman |
| 1/27/2023 | $18.00 → $30.00 | Underweight → Equal-Weight | Morgan Stanley |
| 9/14/2022 | $40.00 | Outperform | SVB Leerink |
| 9/9/2022 | $15.00 | Underweight | Morgan Stanley |
| 3/3/2022 | $36.00 → $28.00 | Underperform → Neutral | Baird |
| 3/3/2022 | $36.00 → $28.00 | Underperform → Neutral | Robert W. Baird |
| 12/21/2021 | $36.00 | Neutral → Underperform | Robert W. Baird |
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious
Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives b
Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases
HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively As previously announced, Phase 3 development in chronic hepatitis B to occur only with a global development and commercialization partner, which has not been secured Vir Biotechnology to streamline the final stages of MARCH Phase 2 study to ensure continued participant benefit and safety, while applying continued financial stewardship The Company reiterates cash runway guidance into mid-2027, based on the current operating plan The Company remains committed to its chronic hepatitis delta program, based on t
- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) - On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025 - 24-week post-treatment data from Phase 2 MARCH study in chronic hepatitis B to be presented at EASL on May 9; Further development requires partner - Strong financial position with approximately $1.0 billion in cash and i
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe
Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data in chronic hepatitis B from MARCH Phase 2 study to be shared in oral presentation Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating c
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China,
First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory submissions and support reimbursement and access Rapid study start indicative of significant unmet need for chronic hepatitis delta treatment Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of the prog
- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Compelling early clinical response signals and promising safety profiles for dual-masked T-cell engagers VIR-5818 and VIR-5500 in heavily pretreated patients with solid tumors, with potential for expanded therapeutic index - Company plans to initiate a Phase 1 study of VIR-5525, its dual-masked EGFR-targeting T-cell engager, in the first half of 2025 - Focused prioritization and disciplined capital deployment
JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously
BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously
JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously
Goldman upgraded Vir Biotechnology from Neutral to Buy and set a new price target of $53.00 from $41.00 previously
Morgan Stanley upgraded Vir Biotechnology from Underweight to Equal-Weight and set a new price target of $30.00 from $18.00 previously
SVB Leerink initiated coverage of Vir Biotechnology with a rating of Outperform and set a new price target of $40.00
Morgan Stanley initiated coverage of Vir Biotechnology with a rating of Underweight and set a new price target of $15.00
Baird upgraded Vir Biotechnology from Underperform to Neutral and set a new price target of $28.00 from $36.00 previously
Robert W. Baird upgraded Vir Biotechnology from Underperform to Neutral and set a new price target of $28.00 from $36.00 previously
Robert W. Baird downgraded Vir Biotechnology from Neutral to Underperform and set a new price target of $36.00
144 - Vir Biotechnology, Inc. (0001706431) (Subject)
144 - Vir Biotechnology, Inc. (0001706431) (Subject)
144 - Vir Biotechnology, Inc. (0001706431) (Subject)
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
DEFA14A - Vir Biotechnology, Inc. (0001706431) (Filer)
DEF 14A - Vir Biotechnology, Inc. (0001706431) (Filer)
S-8 - Vir Biotechnology, Inc. (0001706431) (Filer)
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)